Health
FDA authorizes marketing of new device for short-term treatment of gait deficit in MS patients – News-Medical.Net
Today, the U.S. Food and Drug Administration authorized marketing of a new device indicated for use as a short-term treatment of gait deficit due to mild to moderate…
Today, the U.S. Food and Drug Administration authorized marketing of a new device indicated for use as a short-term treatment of gait deficit due to mild to moderate symptoms from multiple sclerosis (MS). The device is intended to be used by prescription only as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and older. The device, called Portable Neuromodulation Stimulator (PoNS), is a neuromuscular tongue stimulator that consists of a non-implantable apparatus…
-
Noosa News17 hours agoMan charged over allegedly abandoning Arnie the German shepherd in car after claiming dog and vehicle were stolen
-
Noosa News18 hours agoMotorcyclist dies in crash with truck
-
Noosa News18 hours agoSomerville House investigating after teachers’ dossier on students leaked
-
General23 hours agoSmall-town cleaner finds himself in legal battle with EnduroShield over product packaging